Defibrotide is approved for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). VOD is a rare and life-threatening disease that affects approximately 20% of patients who receive high-dose myeloablative conditioning therapy or HSCT. […]